Simone Leyden co-founded NeuroEndocrine Cancer Australia in 2009 after seeing a huge disparity in treatment and support for less common cancers, compared to more common cancers throughout her sister Kate’s neuroendocrine cancer journey.
In 2011 Simone took on the full-time role of Chief Executive Officer of NeuroEndocrine Cancer Australia, which set up her quest for greater access to treatments and diagnostics, to raise funds for the NeuroEndocrine Tumour (NET) Nurse Support Service and research, and raise awareness about NET cancers within the medical community and general public.
Simone’s pursuit of equitable access and investment in breakthrough treatments has now led her to her current role as Director of Global Patient Advocacy and Government Affairs at Telix Radiopharmaceuticals. Radiopharmaceuticals are the gold standard in the diagnosis and treatment of neuroendocrine tumours and are now being used in the clinical setting for cancers such as prostate.
Simone remains co-founder of NeuroEndocrine Cancer Australia and an active board member.